Abstract
A patient with hypogonadotropic hypogonadism owing to endogenous gonadotropin releasing hormone deficiency, who developed Hodgkin's disease is described. Chemotherapy administration caused prolonged and life-threatening myelosuppression; androgen substitution seemed to reverse bone marrow function and to maintain normal peripheral blood counts. Whether or not androgens are a necessary substitution in hypogonadal patients suffering from cancer and undergoing chemotherapy is discussed.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Marrow / drug effects
-
Bone Marrow Diseases / chemically induced*
-
Bone Marrow Diseases / drug therapy
-
Hodgkin Disease / complications
-
Hodgkin Disease / drug therapy*
-
Humans
-
Hypogonadism / complications
-
Hypogonadism / drug therapy*
-
Male
-
Mechlorethamine / administration & dosage
-
Mechlorethamine / adverse effects
-
Pituitary Hormone-Releasing Hormones / deficiency
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Procarbazine / administration & dosage
-
Procarbazine / adverse effects
-
Testosterone / therapeutic use*
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Pituitary Hormone-Releasing Hormones
-
Procarbazine
-
Testosterone
-
Mechlorethamine
-
Vincristine
-
Prednisone